Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > BNN-Bloomberg Nasal Spray to Fight SARS-Cov-2 Coronovirus

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Mar 25, 2021 8:51pm

121 Views

Post# 32883725

RE:RE:RE:BNN-Bloomberg Nasal Spray to Fight SARS-Cov-2 Coronovirus

losingmyshirt wrote: @Enzolini>

Your post is exactly bang on .

The jig was up a long time ago.

When CBD was the "in" thing, Kalytera tried riding the wave.
That failed but then Covid came along and now Kaly is all about
R107 that no one and their dog is interested in.

I like to hang around here to have fun with the goofs that pump here.

..... said Losingmy-short!!